Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Inspyr Therapeutics, Inc. (OTC: NSPX).

Full DD Report for NSPX

You must become a subscriber to view this report.


Recent News from (OTC: NSPX)

Inspyr Therapeutics Announces Research Collaboration with the National Institutes of Health
WESTLAKE VILLAGE, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPX), a clinical-stage biotechnology company, announced the initiation of a new investigator-sponsored preclinical study of its proprietary adenosine receptor modulator (ARM) based compounds. This precli...
Source: GlobeNewswire
Date: October, 23 2017 09:01
Inspyr Therapeutics Announces Research Collaboration with NYU Winthrop Hospital
WESTLAKE VILLAGE, Calif., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPX), a clinical-stage biotechnology company, announced the initiation of a new investigator-sponsored preclinical study of its proprietary compounds generated through its adenosine receptor modulator (A...
Source: GlobeNewswire
Date: October, 04 2017 09:01
Inspyr Therapeutics Announces Research Collaboration with University of Virginia School of Medicine
WESTLAKE VILLAGE, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPX), a clinical-stage biotechnology company, announced the initiation of a new investigator-sponsored preclinical study of its proprietary adenosine receptor modulator-based compounds. This preclinical ...
Source: GlobeNewswire
Date: October, 02 2017 09:01
Inspyr Therapeutics Announces Research Collaboration with University of Virginia School of Medicine
Inspyr Therapeutics Announces Research Collaboration with University of Virginia School of Medicine
Source: OTC Markets
Date: October, 02 2017 00:00
Inspyr Therapeutics and Lewis and Clark Pharmaceuticals Complete Merger
WESTLAKE VILLAGE, Calif. and CHARLOTTESVILLE, Va., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPXD), a clinical-stage biotechnology company, and Lewis and Clark Pharmaceuticals today announced the successful completion of a merger to create an integrated biotechnology co...
Source: GlobeNewswire
Date: September, 13 2017 09:00
Inspyr Therapeutics Announces Private Placement of Senior Convertible Debentures
WESTLAKE VILLAGE, Calif., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPX), a clinical-stage biotechnology company developing a novel prodrug therapeutic for the treatment of cancer, announced today that the company has entered into definitive agreements with institutiona...
Source: GlobeNewswire
Date: September, 12 2017 09:49
Inspyr Therapeutics and Lewis and Clark Pharmaceuticals to Merge
WESTLAKE VILLAGE, Calif. and CHARLOTTESVILLE, Va., May 30, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPXD), a clinical-stage biotechnology company, and Lewis and Clark Pharmaceuticals, a privately-held biotechnology company, today announced that they have entered into an agreemen...
Source: GlobeNewswire
Date: May, 30 2017 16:15
Inspyr Therapeutics Signs Commitment Letter with Milost Global
WESTLAKE VILLAGE, Calif., March 28, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPXD), a clinical-stage biotechnology company developing a novel prodrug therapeutic for the treatment of cancer, announced today that the Company has signed a commitment letter with Milost Global Inc.,...
Source: GlobeNewswire
Date: March, 28 2017 09:00
Inspyr Therapeutics Secures a $100 Million Financing Agreement from Milost Global
Commitment of up to $100 Million in Total Proceeds Transaction Subject to Definitive Agreement WESTLAKE VILLAGE, Calif., March 17, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPXD), a clinical-stage biotechnology company developing a novel prodrug therapeutic for the treatm...
Source: GlobeNewswire
Date: March, 17 2017 09:00
Inspyr Therapeutics Appoints NIH Veterans to Lead New Translational Medicine Initiatives and Pipeline Expansion
WESTLAKE VILLAGE, Calif., March 06, 2017 (GLOBE NEWSWIRE) -- Inspyr Therapeutics (OTCQB:NSPXD), a clinical-stage biotechnology company developing a novel prodrug therapeutic for the treatment of cancer, announced today the appointments of David Maloney, Ph.D. and Matthew Boxer, Ph.D. as Vic...
Source: GlobeNewswire
Date: March, 06 2017 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-170.0070.00990.00990.00757,971
2018-08-16N/A0.0065N/AN/A44
2018-08-150.006050.00650.00650.006052,238
2018-08-14N/A0.0071N/AN/A67
2018-08-13N/A0.0071N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1750,00057,97186.2500Short
2018-08-06667,5321,101,13560.6222Short
2018-08-035,6005,63499.3965Short
2018-07-0955,00059,00093.2203Short
2018-07-0562,300162,30038.3857Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on NSPX.


About Inspyr Therapeutics, Inc. (OTC: NSPX)

Logo for Inspyr Therapeutics, Inc. (OTC: NSPX)

Inspyr Therapeutics develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti tumor activity while minimizing side effects. Inspyr s technology platform combines a powerful, plant derived cytotoxin thapsigargin with a prodrug delivery system that provides for the targeted release of the company s drug candidates within a tumor. Inspyr s lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.

 

 

 

Current Management

  • Christopher Lowe / CEO, President
  • Christopher Lowe /
  • John Montgomery /
  • Scott V. Ogilvie /
  • Claire M. Thom /

Current Share Structure

  • Market Cap: $287,368 - 03/09/2018
  • Authorized: 150,000,000 - 09/30/2016
  • Issue and Outstanding: 9,578,929 - 11/07/2017

 


Recent Filings from (OTC: NSPX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 15 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: December, 21 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 20 2017
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: November, 14 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: November, 03 2017
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: September, 27 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 15 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 12 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: September, 12 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 14 2017

 

 


Daily Technical Chart for (OTC: NSPX)

Daily Technical Chart for (OTC: NSPX)


Stay tuned for daily updates and more on (OTC: NSPX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: NSPX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in NSPX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of NSPX and does not buy, sell, or trade any shares of NSPX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/